The latest price target for Minerva Neurosciences (NASDAQ:NERV) was reported by HC Wainwright & Co. on November 6, 2024. The analyst firm set a price target for $5.00 expecting NERV to rise to within 12 months (a possible 133.64% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Minerva Neurosciences (NASDAQ:NERV) was provided by HC Wainwright & Co., and Minerva Neurosciences reiterated their neutral rating.

There is no last upgrade for Minerva Neurosciences

The last downgrade for Minerva Neurosciences Inc happened on November 10, 2022 when HC Wainwright & Co. changed their price target from N/A to N/A for Minerva Neurosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Minerva Neurosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Minerva Neurosciences was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Minerva Neurosciences (NERV) rating was a reiterated with a price target of $5.00 to $5.00. The current price Minerva Neurosciences (NERV) is trading at is $2.14, which is out of the analyst’s predicted range.